Announcements
Volume 2 Issue 4 2019
Order by
NULL
- Open Access ReviewInhibition of Glutamine Metabolism as a Therapeutic Approach Against Pancreatic Ductal AdenocarcinomaX. Fernandes Miguel, M. Padrón JoséJ. Mol. Clin. Med. 2019, 2(4), 97–110; https://doi.org/10.31083/j.jmcm.2019.04.512153Downloads1Citations106Views
- Open Access ReviewMolecular and immunological rationale for the use of tyrosine kinase inhibitors and immune checkpoint inhibitors in glioblastomasDal Bo Michele, Baboci Lorena, Toffoli GiuseppeJ. Mol. Clin. Med. 2019, 2(4), 111–123; https://doi.org/10.31083/j.jmcm.2019.04.420113Downloads1Citations68Views
- Open Access ReviewSemaphorin-3A and urothelial carcinomaVadas Zahava, Rubinstein Jacob, Bahouth Zaher, Halachmi SarelJ. Mol. Clin. Med. 2019, 2(4), 125–128; https://doi.org/10.31083/j.jmcm.2019.04.506112Downloads55Views
- Open Access Original ResearchChemosensitivity and survival of non-small cell lung carcinoma patients receiving neoadjuvant therapy depend on the expression of multidrug efflux transportersStankovic Tijana, Stojsic Jelena, Dragoj Miodrag, Milovanovic Zorka, ... Bankovic JasnaJ. Mol. Clin. Med. 2019, 2(4), 129–135; https://doi.org/10.31083/j.jmcm.2019.04.324114Downloads57Views